C. Giorgetti
About
C. Giorgetti is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research.
According to data from OpenAlex, C. Giorgetti has authored 33 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Pulmonary and Respiratory Medicine, 23 papers in Oncology and 4 papers in Cancer Research. Recurrent topics in C. Giorgetti's work include Advanced Breast Cancer Therapies (22 papers), HER2/EGFR in Cancer Research (17 papers) and Cancer Treatment and Pharmacology (14 papers). C. Giorgetti is often cited by papers focused on Advanced Breast Cancer Therapies (22 papers), HER2/EGFR in Cancer Research (17 papers) and Cancer Treatment and Pharmacology (14 papers). C. Giorgetti collaborates with scholars based in United States, Italy and United Kingdom. C. Giorgetti's co-authors include Cynthia Huang Bartlett, Nicholas C. Turner, Massimo Cristofanilli, Sherene Loi, Nadia Harbeck, Fabrice André, Sibylle Loibl, Hiroji Iwata, Jungsil Ro and Sunil Verma and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.
In The Last Decade
C. Giorgetti
33 papers receiving 3.0k citations
Hit Papers
Peers
C. Giorgetti
Denis Péré-Vergé France
Ignacio Gil‐Bazo Spain
Radj Gervais France
G. Peruzzotti Italy
C. Montoto-Grillot France
Yaroslav Shparyk United States
Faiza Khemissa-Akouz France
N. Moore Switzerland
Grazyna Liebérman United States
Lorenzo Gianni Italy
Citations per year, relative to C. Giorgetti C. Giorgetti (= 1×)
peers
Denis Péré-Vergé
Countries citing papers authored by C. Giorgetti
Since
Specialization
Citations
This map shows the geographic impact of C. Giorgetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Giorgetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Giorgetti more than expected).
Fields of papers citing papers by C. Giorgetti
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by C. Giorgetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Giorgetti. The network helps show where C. Giorgetti may publish in the future.
Co-authorship network of co-authors of C. Giorgetti
This figure shows the co-authorship network connecting the top 25 collaborators of C. Giorgetti. A scholar is included among the top collaborators of C. Giorgetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Giorgetti. C. Giorgetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Finn, Richard S., Massimo Cristofanilli, Johannes Ettl, et al.. (2020). Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 and PALOMA-3 clinical trials. Breast Cancer Research and Treatment. 184(1). 23–35.
2.
Turner, Nicholas C., Yuan Liu, Zhou Zhu, et al.. (2019). Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 37(14). 1169–1178.
3.
Turner, Nicholas C., Yuan Liu, Zhou Zhu, et al.. (2018). Cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial. Clinical Trials. 78(13).
4.
Cristofanilli, Massimo, Angela DeMichele, C. Giorgetti, et al.. (2018). Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer in PALOMA-3. European Journal of Cancer. 104. 21–31.
5.
Turner, Nicholas C., Richard S. Finn, Miguel Martín, et al.. (2018). Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Annals of Oncology. 29(3). 669–680.
6.
Cristofanilli, Massimo, Dennis J. Slamon, Jungsil Ro, et al.. (2018). Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. Annals of Oncology. 29. viii708–viii708.
7.
Turner, Nicholas C., Yuan Liu, Zhou Zhu, et al.. (2018). Abstract CT039: Cyclin E1 (CCNE1) expression associates with benefit from palbociclib in metastatic breast cancer (MBC) in the PALOMA3 trial. Cancer Research. 78(13_Supplement). CT039–CT039.
8.
Cristofanilli, Massimo, Angela DeMichele, C. Giorgetti, et al.. (2017). Predictors of prolonged benefit from palbociclib (PAL) plus fulvestrant (F) in women with endocrine-resistant hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) in PALOMA-3.. Journal of Clinical Oncology. 35(15_suppl). 1050–1050.
9.
Loibl, Sibylle, Angela DeMichele, Nicholas C. Turner, et al.. (2016). Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2- metastatic breast cancer. Annals of Oncology. 27. vi80–vi80.
10.
Foukakis, Theodoros, John Lövrot, Linda S. Lindström, et al.. (2015). Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer. Molecular Oncology. 9(7). 1384–1391.
11.
Turner, Nicholas C., Jungsil Ro, Fabrice André, et al.. (2015). Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 373(3). 209–219.
12.
Bergh, Jonas, Gabriella Mariani, Fátima Cardoso, et al.. (2012). Clinical and pharmacokinetic study of sunitinib and docetaxel in women with advanced breast cancer. The Breast. 21(4). 507–513.
13.
Sorensen, Sonja, Feng Pan, Connie Chen, et al.. (2012). INCIDENCE-BASED COST-OF-ILLNESS MODEL FOR METASTATIC BREAST CANCER IN THE UNITED STATES. International Journal of Technology Assessment in Health Care. 28(1). 12–21.
14.
Cardoso, Fátima, Jean‐Luc Canon, Dino Amadori, et al.. (2012). An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer. The Breast. 21(6). 716–723.
15.
Bergh, Jonas, Igor Bondarenko, Mikhail Lichinitser, et al.. (2012). First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. Journal of Clinical Oncology. 30(9). 921–929.
16.
Bergh, Jonas, Alain Lortholary, Xin Huang, et al.. (2010). Sunitinib (SU) in combination with docetaxel (D) versus D alone for the first-line treatment of advanced breast cancer (ABC).. Journal of Clinical Oncology. 28(18_suppl). LBA1010–LBA1010.
17.
Cardoso, Fátima, J-L. Canon, D. Amadori, et al.. (2009). Tolerability of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2+advanced breast cancer : Abstract #4120. Cancer Research. 69(2).
18.
Karthaus, Meinolf, Albrecht Kretzschmar, H. Kröning, et al.. (2005). Dalteparin for prevention of catheter-related complications in cancer patients with central venous catheters: final results of a double-blind, placebo-controlled phase III trial. Annals of Oncology. 17(2). 289–296.
19.
Molinari, Agnese, C. Giorgetti, J. Lansen, et al.. (1992). Thrombomodulin Is a Cofactor for Thrombin Degradation of Recombinant Single-Chain Urokinase Plasminogen Activator "In Vitro" and in a Perfused Rabbit Heart Model. Thrombosis and Haemostasis. 67(2). 226–232.
20.
Molinari, Agnese, et al.. (1992). Differential detection of single chain urokinase-type plasminogen activator and two chain urokinase-type plasminogen activator in human and monkey plasma. Fibrinolysis and Proteolysis. 6(1). 17–26.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Denis Péré-Vergé Breakdown of academic impact, for papers by Ignacio Gil‐Bazo Breakdown of academic impact, for papers by Radj Gervais Breakdown of academic impact, for papers by G. Peruzzotti Breakdown of academic impact, for papers by C. Montoto-Grillot Breakdown of academic impact, for papers by Yaroslav Shparyk Breakdown of academic impact, for papers by Faiza Khemissa-Akouz Breakdown of academic impact, for papers by N. Moore Breakdown of academic impact, for papers by Grazyna Liebérman Breakdown of academic impact, for papers by Lorenzo Gianni